Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nolupus.
I don't think you are in a position to lecture people on doing their own research to check on the truth of your unchecked and unresearched statements such as your latest on CNRS and IMM. You should read what is written on this subject in the Immupharma website before opining on this. In it you would have read that Immupharma has exclusive rights to commercialise the CNRS patents. In return, CNRS will receive 12% of Imm's revenue from royalties arising from this effort.
It is also mentioned that a new agreement on collaboration between CNRS and IMM is being discussed.
But you can find this for yourself before making statements on the subject, or are you too lazy?
Wigwammer,
I personaly Take offense to your 'attacks' on my 'person'
Ownership of the patents and licensing royalties are Two different matters...
Just GO and DO YOUR OWN research before throwing stones !!
Funny, in the first hour of trading the sp only rose modestly but as commented on below did the MM run out of shares?
The current rise is around 25% which is more than I hoped for after reading the RNS this morning.
Hold onto your shares and enjoy the ride!
I agree supermobileman. It is nothing like 50/50. And to refer to them as “joint partners” without providing detail is highly misleading. From memory - it was about 3% of sales. Mr nolupus has some peculiar weakness where he likes to be seen as “Mr
Moral” - but there is nothing moral about repeatedly misleading people, or owning the shares while encouraging others to do the opposite.
It is not a 50/50 split with CNRS regarding patent or otherwise. CNRS I believed have 12% (or thereabout) of Immupharma's income arising from Lupuzor deals, royalties etc.
MMs caught out and running out of shares , very sticky hands today , hardly any sells , 3p incoming if this carries on
Wigwammer,
As far as i am aware, they are joint holders 50/50 With the CNRS...
Wildbunch will surely clarify this :-)
Nolupus,
Certain details lacking from your post too. What percentage of the patent do immupharma own?
Cautious optimism growing , steady low volume buying with very few sells today and climbing the share risers table, bulls could be moving in .
3.0p coming
A bit lukewarm but I remain cautiously optimistic that the P3 trial will result in a drug coming to market for Lupus patients which in return should see a multi bag sp gain from here. Protecting the IP just good housekeeping, results or not from the P3 trial will determine where the sp goes.
Wigwammer,
Whilst we may agree on certain details ( or lack of )
One should remember that IMM are only one of the joint patent holders .
It’s even more bizarre that Avion have sustained interest, without any clear strategy to protect the IP. Perhaps they are just not telling us what they know? I hope so, because what we do know is they currently have little protection.
Well of course. Not much point having IP if it isn’t protected. Have they only just considered this?! So where is the detail on how they plan to do it… it’s just a very strange RNS.
Wig
Maybe its what a potential partner has asked for. Dotting the i*s and crossing the t's.
Protection ois essential in this game.
Gla
Initiating a patent protection strategy?! Well yes, patent protection is a good idea if you’re an IP based company. Almost no detail whatsoever about how they plan to do it. Strange and bizarre communication.
Maybe thats what the potential partners want before they seal the deal.
Remember we going for 2 indications with this drug.
Back to work for me after 2 weeks off.
Gla
They have discussions with a deal looks like.
He he he he.
Quite close Nolupus or should I say Tim ?
Yes but for good reason, extending patent life suggests the company and its backers expect the next Phase 3 trial to produce results.
UP WE GO
Hope everyone had a nice relaxing BH and Easter
Frits. Everyone is entitled to an opinion. Nolupus makes a valid point.
Nobinpus,
By your own admission, you have stated several times that you are not invested in IMM! Stop changing the story to suit your negative passive aggressive narrative.
Frits
Wildbunch,
They may be awaiting on some patent news before concluding any major deal..
Let's wait and see